An Open-Label, Single Arm, Phase Ib/II Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2012
At a glance
- Drugs Afuresertib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 23 Mar 2012 Planned End Date changed from 1 Oct 2013 to 30 Nov 2011 as reported by ClinicalTrials.gov.
- 23 Mar 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.